The transformation biology of secondary acute myeloid leukaemia (AML) from
myelodysplastic syndromes (MDSs) is still not fully understood. We performed paired self …

Myelodysplastic syndrome (MDS) describes a family of blood disorders driven by the clonal
expansion of mutated blood cells that can evolve into secondary acute myeloid leukemia …

Progression from myelodysplastic syndromes (MDS) to secondary acute myeloid leukemia
(AML) is associated with the acquisition and expansion of subclones. Our understanding of …

The genetics behind the progression of myelodysplasia to secondary acute myeloid
leukemia (sAML) is poorly understood. In this study, we profiled somatic mutations and their …

The myelodysplastic syndromes (MDS) are frequently associated with clonally restricted
cytogenetic abnormalities, but until recently, the molecular pathobiology underlying this …

Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders
that originate from the hematopoietic stem and progenitor cells that lead to the development …

Abstract Purpose of Review To understand how myelodysplastic syndromes (MDS)
transform to AML and to describe how transformation can be predicted and prevented …

In 1956, the diploid number of chromosomes in humans was established as 46, opening the
door for cytogeneticists to identify numerical and structural chromosome abnormalities that …

Knowledge of the molecular and clonal characteristics in the myelodysplastic syndromes
(MDS) and during progression to acute myeloid leukaemia (AML) is essential to understand …

Myelodysplastic syndrome (MDS) includes a heterogeneous group of clonal haematological
stem cell disorders characterized by dysplasia, cytopenias, ineffective haematopoiesis, and …